SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease
So if GLP one is considered appropriate, uh, because there is persistent visceral adiposity, you know, she's doing everything where she's like, I am eating and I am training and my like, belly fat that's deep will not budge
According to the WHO, the mortality rate associated with diabetes has increased by 3% over the past two decades, resulting in approximately 284,049 deaths in 2019, predominantly impacting low- and middle-income countries [3]
The treatment plan depends on the cause and severity
Highlights The first incretin hormone, gastric inhibitory peptide, was identified in the early 1970s, followed by the discovery of glucagonlike peptide 1 (GLP-1) in the 1980s [1]
That way, you lose weight safely in a caring setting and have the tools and knowledge to keep the weight off and stay healthy for the rest of your life
